Journal
EINSTEIN-SAO PAULO
Volume 14, Issue 1, Pages 99-103Publisher
INST ISRAELITA ENSINO & PESQUISA ALBERT EINSTEIN
DOI: 10.1590/S1679-45082016RB3475
Keywords
Nanomedicine; Liposomes; Nanoparticles; Neoplasms/drug therapy; Drug delivery systems
Categories
Funding
- Instituto Israelita de Ensino e Pesquisa Albert Einstein (IIEPAE)
- Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq)
- Financiadora de Estudos e Projetos (FINEP)
- Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES)
- Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP)
Ask authors/readers for more resources
The use of nanocarriers as drug delivery systems for therapeutic or imaging agents can improve the pharmacological properties of commonly used compounds in cancer diagnosis and treatment. Advances in the surface engineering of nanoparticles to accommodate targeting ligands turned nanocarriers attractive candidates for future work involving targeted drug delivery. Although not targeted, several nanocarriers have been approved for clinical use and they are currently used to treat and/or diagnosis various types of cancers. Furthermore, there are several formulations, which are now in various stages of clinical trials. This review examined some approved formulations and discussed the advantages of using nanocarriers in cancer therapy.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available